AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$PTHS

Friedberg Ezra M sold $12K of PTHS

Friedberg Ezra M sold 558 shares of Pelthos Therapeutics Inc. (PTHS) at $20.72 on 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Friedberg Ezra M
Published Oct 6, 2026, 9:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PTHS
Neutral
high confidence
Mentioned
$PTHS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PTHSNeutralLow
01

Why it matters

The disclosed sale is a routine insider transaction with limited market impact.

02

Market read

Small insider sale with negligible effect on stock price.

03

What to watch

Potential upcoming clinical data could offset the minor sell pressure.

Relevance 2/10Novelty 2/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$PTHSNeutralHigh confidence
Context

Director Friedberg Ezra M sold 558 shares for $11.5K via a 10b5-1 plan, reducing his holdings to 80,484 shares.

Expected impact

likely pressure as the market prices in the insider sell

Evidence & confidence

The transaction size is small relative to market cap and typical trading volume, so impact is limited.

Market effects

Sector

None significant; biotech sector unchanged.

Regional

No regional effect.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale may signal insider confidence if the remaining stake is still large.

Key entities

  • Company
    Pelthos Therapeutics Inc.

    Biotech firm listed on NASDAQ under ticker PTHS.

  • Individual
    Friedberg Ezra M

    Director of Pelthos Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PTHS insider trading history →

Related articles

$PTHSHigh

Piper Sandler cuts Pelthos stock price target on merger dilution

Piper Sandler reduced its price target for Pelthos Therapeutics (NYSE:PTHS) to $21 from $48, citing merger dilution and increased R&D spending. The company reported a Q3 2026 net loss of $2.04 per share on $15.4M revenue, missing EPS estimates but beating revenue expectations. Pelthos announced a merger with Castle Creek Biosciences, adding a Phase III gene therapy. The stock is down 77% over the past year, trading at $8.03.

investing.com
$PTHSMed

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

finance.yahoo.com
$PTHSMed

Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update

Pelthos Therapeutics Inc. (PTHS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update Zelsuvmi ® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 2025 12,384 Zelsuvmi units were dispe

SEC EDGAR 8-K
$PTHSHighAI 8/10

Pelthos and Castle Creek plan merger to target skin diseases

Pelthos Therapeutics (PTHS) will merge with Castle Creek Biosciences, focusing on skin diseases. The deal, approved by both boards, is expected to close by Q1 2027. Castle Creek shareholders will receive 5.2 million Pelthos shares, with potential for more if D-Fi, a gene-modified cell therapy, gains FDA approval. The combined company will trade on the NYSE American under PTHS.

finance.yahoo.com